Conversely, transcriptionally upregulating Gln synthetase, which converts Glu to Gln, enhanced LC3-II levels in a modified colon carcinoma cell line DLD1 that allowed for controlled activation of FOXO3 [52]. Here, FOXO3 is linked to colon carcinoma.